Stock Taper 
CRMD
$8.20
▼ DOWN 0.36% (-0.03)
KEY STATISTICS
Market Cap$643.31 M
52w High$14.96
52w Low$6.13
Dividend Yield—
Frequency—
P/E4.34
Volume1.50M
Shares Out.78.45M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Joseph Todisco
COMPENSATION 2026
Salary$684,353
Stock Awards$4,492,500
Incentive Plan Pay$865,072
All Other Comp.$59,251
Total$6,101,176
ABOUT
SECTOR
Healthcare
WENT PUBLIC
May 13, 2010
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
191
PRICE TARGET
Target High$14.00
Target Low$13.00
Target Median$13.50
Target Consensus$13.50
UPCOMING EARNINGS
DateNov 11, 2026
DayWednesday
Rev. Est.$53.27M
NOV
11
WED
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2019-03-26 | Reverse | 1:5 |
PRICE
$8.20 ▼ DOWN 0.36% (−$0.03)About CorMedix Inc.
https://www.cormedix.com ↗CorMedix Inc. develops and commercializes therapies like DefenCath/Neutrolin to prevent infections and thrombosis related to central venous catheters in clinical settings worldwide.
INDUSTRY
Biotechnology
A PRODUCT CORMEDIX INC. IS KNOWN FOR
DefenCath®
DefenCath® is the first FDA-approved antimicrobial catheter lock solution, containing taurolidine and heparin, designed to reduce bloodstream infections in adult hemodialysis patients with central venous catheters, and is CorMedix’s primary commer...
Revenue by Products
| Icon | PRODUCT | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
 | Product | $101.55M | $202.8M ▲ | $121.92M ▼ | $94.34M ▼ |
 | Contract Revenue | — | — | $5.51M | $4.97M ▼ |
 | Grant Income | — | — | — | $2.62M |
Revenue by Geography
| Map | REGION | FY2020 | FY2021 |
|---|---|---|---|
 | Europe | $237.03K | $190.94K ▼ |
ETFS HOLDING THIS STOCK
ETFS HOLDING
119
LISTED HERE
25
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
49.47%
HOLDERS
281
TOP 12 OF 281 · RANKED BY POSITION SIZE
Blackrock, Inc.
Deep Track Capital, LP
Vanguard Group Inc
Blackrock Inc.
Marshall Wace, Llp
Deerfield Management Company, L.P. (Series C)
State Street Corp
Royce & Associates LP
Geode Capital Management, LLC
Ubs Group AG
Citadel Advisors LLC
Oberweis Asset Management Inc/
RATINGS SNAPSHOT
Overall rating: A-
Discounted Cash Flow1
Return On Equity5
Return On Assets5
Debt To Equity2
Price To Earnings3
Price To Book4
Overall Score4
INSIDER TRADES
★
OFFICER: CHIEF OPERATING OFFICER
Hurlburt Elizabeth
Purchase · 36.0K shares
2026-02-04
★
OFFICER: CHIEF LEGAL OFFICER
Zelnick Kaufman Beth
Purchase · 36.0K shares
2026-02-04
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Todisco Joseph
Purchase · 77.2K shares
2026-02-04
★
OFFICER: CHIEF FINANCIAL OFFICER
Blum Susan
Purchase · 72.8K shares
2026-01-23
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 3
OUTPERFORM 2
MARKET OUTPERFORM 2
7 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 TNGX | $23.88 | COMPARE |
 NBTX | $43.55 | COMPARE |
 PVLA | $142.04 | COMPARE |
 SEPN | $40.00 | COMPARE |
 BCAX | $23.90 | COMPARE |
 SVRA | $5.59 | COMPARE |
 KURA | $11.89 | COMPARE |
 ABUS | $5.21 | COMPARE |